20/06/2024
Critique of the Code of Good Manufacturing Practice (First Amendment), 2079
The First Amendment to Nepal's Code of Good Manufacturing Practice (GMP) introduces several changes aimed at strengthening quality assurance and risk management in pharmaceutical manufacturing. While these changes are generally positive, some aspects warrant further consideration and potential revision:
Positives:
Emphasis on Quality: The amendment reinforces the importance of a robust Pharmaceutical Quality System (PQS), integrating Good Manufacturing Practices (GMP) and Quality Risk Management (QRM). This aligns with international best practices and promotes continuous improvement in drug quality.
Clarity of Roles and Responsibilities: The amendment explicitly requires the top management of pharmaceutical companies to clearly define roles, responsibilities, and authorities within the PQS, ensuring accountability and effective implementation.
Risk-Based Approach: The introduction of QRM principles allows for a more systematic and proactive approach to identifying and mitigating risks throughout the drug manufacturing process.
Flexibility: The amendment introduces some flexibility in manufacturing certain drug classes (e.g., steroid inhalers) in shared facilities with general medicines, provided risk assessment and control measures are in place. This could potentially reduce costs and streamline production processes.
Areas for Improvement:
Implementation Challenges: The amendment lacks specific guidance on how companies should implement the new requirements, particularly regarding QRM. This could lead to inconsistencies in interpretation and implementation across different manufacturers.
Limited Scope: The amendment focuses primarily on quality assurance and risk management, but does not address other critical aspects of GMP, such as personnel qualification and training, documentation, and complaint handling.
Need for Stakeholder Engagement: The amendment process may not have involved sufficient consultation with all relevant stakeholders, including industry representatives, healthcare professionals, and consumer groups. Broader stakeholder engagement could enhance the relevance and effectiveness of the revised GMP.
Enforcement and Monitoring: The amendment does not specify how the DDA will enforce the new requirements and monitor compliance. Robust enforcement and monitoring mechanisms are essential to ensure the effectiveness of the GMP.
Recommendations:
Develop Implementation Guidelines: The DDA should issue detailed guidelines on how to implement the new requirements, particularly regarding QRM, to ensure consistency and clarity across the industry.
Expand Scope: Future amendments should address other critical aspects of GMP not covered in this amendment, such as personnel qualification and training, documentation, and complaint handling.
Enhance Stakeholder Engagement: The DDA should actively engage with all relevant stakeholders in the development and revision of GMP to ensure their concerns and perspectives are taken into account.
Strengthen Enforcement and Monitoring: The DDA should establish clear enforcement mechanisms and regularly monitor compliance with GMP to ensure the safety and quality of pharmaceutical products in Nepal.
Consider International Standards: Aligning the Nepalese GMP with international standards, such as those set by the World Health Organization (WHO), could enhance the credibility and acceptance of Nepalese pharmaceutical products in global markets.
Overall, the First Amendment represents a positive step towards strengthening GMP in Nepal. However, addressing the identified areas for improvement and incorporating the recommended changes could further enhance the effectiveness and impact of the revised GMP, ultimately benefiting both the pharmaceutical industry and the public health of Nepal.
